The disparity in the prognostic significance of age between IDH-wildtype glioblastoma and IDH-mutant gliomas is likely driven by the inherently aggressive nature of IDH-wildtype tumors, age-related immune dysfunction, and reduced treatment tolerance to chemotherapy and radiotherapy given the older age at diagnosis for glioblastoma patients, whereas the more indolent course of IDH-mutant gliomas may attenuate the influence of age on prognosis (84). The gene discussed is IDH2; the disease is glioblastoma.